KEGG   PATHWAY: ko05219Help
Entry
ko05219                     Pathway                                

Name
Bladder cancer
Description
The urothelium covers the luminal surface of almost the entire urinary tract, extending from the renal pelvis, through the ureter and bladder, to the proximal urethra. The majority of urothelial carcinoma are bladder carcinomas, and urothelial carcinomas of the renal pelvis and ureter account for only approximately 7% of the total. Urothelial tumours arise and evolve through divergent phenotypic pathways. Some tumours progress from urothelial hyperplasia to low-grade non-invasive superficial papillary tumours. More aggressive variants arise either from flat, high-grade carcinoma in situ (CIS) and progress to invasive tumours, or they arise de novo as invasive tumours. Low-grade papillary tumors frequently show a constitutive activation of the receptor tyrosine kinase-Ras pathway, exhibiting activating mutations in the HRAS and fibroblast growth factor receptor 3 (FGFR3) genes. In contrast, CIS and invasive tumors frequently show alterations in the TP53 and RB genes and pathways. Invasion and metastases are promoted by several factors that alter the tumour microenvironment, including the aberrant expression of  E-cadherins (E-cad), matrix metalloproteinases (MMPs), angiogenic factors such as vascular endothelial growth factor (VEGF).
Class
Human Diseases; Cancers
BRITE hierarchy
Pathway map
Bladder cancer
ko05219

All organismsOrtholog table
Disease
H00022  
Bladder cancer
Orthology
K05094  
fibroblast growth factor receptor 3 [EC:2.7.10.1]
K02833  
GTPase HRas
K07827  
GTPase KRas
K07828  
GTPase NRas
K08845  
A-Raf proto-oncogene serine/threonine-protein kinase [EC:2.7.11.1]
K04365  
B-Raf proto-oncogene serine/threonine-protein kinase [EC:2.7.11.1]
K04366  
RAF proto-oncogene serine/threonine-protein kinase [EC:2.7.11.1]
K04368  
mitogen-activated protein kinase kinase 1 [EC:2.7.12.2]
K04369  
mitogen-activated protein kinase kinase 2 [EC:2.7.12.2]
K04371  
mitogen-activated protein kinase 1/3 [EC:2.7.11.24]
K04445  
ribosomal protein S6 kinase alpha-5 [EC:2.7.11.1]
K04377  
Myc proto-oncogene protein
K09850  
Ras association domain-containing protein 1
K08803  
death-associated protein kinase [EC:2.7.11.1]
K06621  
cyclin-dependent kinase inhibitor 2A
K06643  
E3 ubiquitin-protein ligase Mdm2 [EC:6.3.2.19]
K04451  
tumor protein p53
K06625  
cyclin-dependent kinase inhibitor 1A
K04503  
cyclin D1
K02089  
cyclin-dependent kinase 4 [EC:2.7.11.22]
K06618  
retinoblastoma-associated protein
K17454  
transcription factor E2F1
K09389  
transcription factor E2F2
K06620  
transcription factor E2F3
K16857  
thrombospondin 1
K04357  
epidermal growth factor
K05083  
receptor tyrosine-protein kinase erbB-2 [EC:2.7.10.1]
K04361  
epidermal growth factor receptor [EC:2.7.10.1]
K00758  
thymidine phosphorylase [EC:2.4.2.4]
K05448  
vascular endothelial growth factor A
K01388  
matrix metalloproteinase-1 (interstitial collagenase) [EC:3.4.24.7]
K01398  
matrix metalloproteinase-2 (gelatinase A) [EC:3.4.24.24]
K01403  
matrix metalloproteinase-9 (gelatinase B) [EC:3.4.24.35]
K10030  
interleukin 8
K05689  
cadherin 1, type 1, E-cadherin
Reference
  Authors
Mitra AP, Datar RH, Cote RJ.
  Title
Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.
  Journal
J Clin Oncol 24:5552-64 (2006)
Reference
  Authors
Wolff EM, Liang G, Jones PA.
  Title
Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.
  Journal
Nat Clin Pract Urol 2:502-10 (2005)
Reference
  Authors
Wu XR.
  Title
Urothelial tumorigenesis: a tale of divergent pathways.
  Journal
Nat Rev Cancer 5:713-25 (2005)
Reference
  Authors
Brown NS, Jones A, Fujiyama C, Harris AL, Bicknell R.
  Title
Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors.
  Journal
Cancer Res 60:6298-302 (2000)
Reference
  Authors
Bellmunt J, Hussain M, Dinney CP.
  Title
Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.
  Journal
Crit Rev Oncol Hematol 46 Suppl:S85-104 (2003)
Reference
  Authors
Sugano K, Kakizoe T.
  Title
Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging.
  Journal
Nat Clin Pract Urol 3:642-52 (2006)
Reference
  Authors
Dunn KL, Espino PS, Drobic B, He S, Davie JR.
  Title
The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling.
  Journal
Biochem Cell Biol 83:1-14 (2005)
Reference
  Authors
Williams SG, Stein JP.
  Title
Molecular pathways in bladder cancer.
  Journal
Urol Res 32:373-85 (2004)

DBGET integrated database retrieval system